These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
24. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro]. Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569 [TBL] [Abstract][Full Text] [Related]
25. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line. Yin XY; Wang L; Lu MD; Li BJ; Huang JF Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097 [TBL] [Abstract][Full Text] [Related]
26. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]. Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734 [TBL] [Abstract][Full Text] [Related]
27. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
28. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Xu DH; Zhou CH; Xia YP; Qiu ZY; Wu YZ; Jia ZC; Zhou W Acta Pharmacol Sin; 2007 May; 28(5):695-702. PubMed ID: 17439726 [TBL] [Abstract][Full Text] [Related]
29. [The comparison of inducing specific CTL by two methods of leukemia cell antigen loading of DCs and fusion of DCs with leukemia cells]. Sheng LX; Qiu GQ; Xie XB; Gu WY; Wang ZL; Wu HQ Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):205-9. PubMed ID: 15766407 [TBL] [Abstract][Full Text] [Related]
30. [Dendritic cells originated from the peripheral blood in chronic hepatitis B patients can induce specific T cell immune response]. Li RB; Chen HS; Xie Y; Fei R; Cong X; Fan CL; Wang SX; Wei L; Wang Y Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):588-91. PubMed ID: 14572332 [TBL] [Abstract][Full Text] [Related]
31. Induction of alpha-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells. Zhang HM; Zhang LW; Ren J; Fan L; Si XM; Liu WC Cell Immunol; 2006 Feb; 239(2):144-50. PubMed ID: 16814271 [TBL] [Abstract][Full Text] [Related]
32. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer]. Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621 [TBL] [Abstract][Full Text] [Related]
34. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. Shilyansky J; Jacobs P; Doffek K; Sugg SL J Pediatr Surg; 2007 Jan; 42(1):54-61; discussion 61. PubMed ID: 17208541 [TBL] [Abstract][Full Text] [Related]
35. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947 [TBL] [Abstract][Full Text] [Related]
36. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes. Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660 [TBL] [Abstract][Full Text] [Related]
37. FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. Dauer M; Schad K; Herten J; Junkmann J; Bauer C; Kiefl R; Endres S; Eigler A J Immunol Methods; 2005 Jul; 302(1-2):145-55. PubMed ID: 15992809 [TBL] [Abstract][Full Text] [Related]
38. [Epitopic multiple antigen peptide from α-fetoprotein elicit antitumor immune response in vitro and ex vivo]. Fan ZJ; Zhang SR Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1138-42. PubMed ID: 22781777 [TBL] [Abstract][Full Text] [Related]
39. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043 [TBL] [Abstract][Full Text] [Related]
40. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice. Zhang W; Yang H; Wang Z; Jim X Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]